A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: Interim Clinical Trial Results
Matthew A Petoe, Samuel A Titchener, Maria Kolic, William G Kentler, Carla J Abbott, David A X Nayagam, Elizabeth K Baglin, Jessica Kvansakul, Nick Barnes, Janine G Walker, Stephanie B Epp, Kiera A Young, Lauren N Ayton, Chi D Luu, Penelope J Allen, Bionics Institute and Centre for Eye Research Australia Retinal Prosthesis Consortium, Peter J Blamey, Robert J Briggs, Owen Burns, Dean Johnson, Lewis Karapanos, Hugh J McDermott, Myra B McGuinness, Rodney E Millard, Peter M Seligman, Robert K Shepherd, Mohit N Shivdasani, Nicholas C Sinclair, Patrick C Thien, Joel Villalobos, Chris E Williams, Jonathan Yeoh, Matthew A Petoe, Samuel A Titchener, Maria Kolic, William G Kentler, Carla J Abbott, David A X Nayagam, Elizabeth K Baglin, Jessica Kvansakul, Nick Barnes, Janine G Walker, Stephanie B Epp, Kiera A Young, Lauren N Ayton, Chi D Luu, Penelope J Allen, Bionics Institute and Centre for Eye Research Australia Retinal Prosthesis Consortium, Peter J Blamey, Robert J Briggs, Owen Burns, Dean Johnson, Lewis Karapanos, Hugh J McDermott, Myra B McGuinness, Rodney E Millard, Peter M Seligman, Robert K Shepherd, Mohit N Shivdasani, Nicholas C Sinclair, Patrick C Thien, Joel Villalobos, Chris E Williams, Jonathan Yeoh
Abstract
Purpose: To report the initial safety and efficacy results of a second-generation (44-channel) suprachoroidal retinal prosthesis at 56 weeks after device activation.
Methods: Four subjects, with advanced retinitis pigmentosa and bare-light perception only, enrolled in a phase II trial (NCT03406416). A 44-channel electrode array was implanted in a suprachoroidal pocket. Device stability, efficacy, and adverse events were investigated at 12-week intervals.
Results: All four subjects were implanted successfully and there were no device-related serious adverse events. Color fundus photography indicated a mild postoperative subretinal hemorrhage in two recipients, which cleared spontaneously within 2 weeks. Optical coherence tomography confirmed device stability and position under the macula. Screen-based localization accuracy was significantly better for all subjects with device on versus device off. Two subjects were significantly better with the device on in a motion discrimination task at 7, 15, and 30°/s and in a spatial discrimination task at 0.033 cycles per degree. All subjects were more accurate with the device on than device off at walking toward a target on a modified door task, localizing and touching tabletop objects, and detecting obstacles in an obstacle avoidance task. A positive effect of the implant on subjects' daily lives was confirmed by an orientation and mobility assessor and subject self-report.
Conclusions: These interim study data demonstrate that the suprachoroidal prosthesis is safe and provides significant improvements in functional vision, activities of daily living, and observer-rated quality of life.
Translational relevance: A suprachoroidal prosthesis can provide clinically useful artificial vision while maintaining a safe surgical profile.
Conflict of interest statement
Disclosure: M.A. Petoe, BI (P), BVT (F,R); S.A. Titchener, BVT (F); M. Kolic, BVT (F,R); W.G. Kentler, BVT (F); C.J. Abbott, BVT (F,R); D.A.X. Nayagam, BI (P), BVT (F); E.K. Baglin, BVT (F,R); J. Kvansakul, BVT (F); N. Barnes, ANU (P), BVT (F); J.G. Walker, BVT (F); S.B. Epp, BVT (F); K.A. Young, BVT (F); L.N. Ayton, none; C.D. Luu, BVT (F); P.J. Allen, BVT (F), CERA (P)
Figures
References
- Dias MF, Joo K, Kemp JA, et al. .. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res. 2018; 63: 107–131.
- Russell S, Bennett J, Wellman JA, et al. .. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017; 390: 849–860.
- Ayton LN, Barnes N, Dagnelie G, et al. .. An update on retinal prostheses. Clin Neurophysiol. 2020; 131: 1383–1398.
- Luo YH-L, da Cruz L.. The Argus II retinal prosthesis system. Prog Retin Eye Res. 2016; 50: 89–107.
- Palanker D, Le Mer Y, Mohand-Said S, Muqit M, Sahel JA. Photovoltaic restoration of central vision in atrophic age-related macular degeneration. Ophthalmology. 2020; 127: 1097–1104.
- Edwards TL, Cottriall CL, Xue K, et al. .. Assessment of the electronic retinal implant Alpha AMS in restoring vision to blind patients with end-stage retinitis pigmentosa. Ophthalmology. 2018; 125: 432–443.
- Stingl K, Bartz-Schmidt KU, Besch D, et al. .. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc R Soc B Biol Sci. 2013; 280: 20130077.
- Ayton LN, Blamey PJ, Guymer RH, et al. .. First-in-human trial of a novel suprachoroidal retinal prosthesis. PLoS One. 2014; 9: e115239.
- Villalobos J, Nayagam DAX, Allen PJ, et al. .. A wide-field suprachoroidal retinal prosthesis is stable and well tolerated following chronic implantation. Invest Ophth Vis Sci. 2013; 54: 3751–3762.
- Fujikado T, Kamei M, Sakaguchi H, et al. .. One-year outcome of 49-channel suprachoroidal–transretinal stimulation prosthesis in patients with advanced retinitis pigmentosa. Invest Ophth Vis Sci. 2016; 57: 6147–6157.
- Ayton LN, Apollo NV, Varsamidis M, Dimitrov PN, Guymer RH, Luu CD.. Assessing residual visual function in severe vision loss. Invest Ophth Vis Sci. 2014; 55: 1332–1338.
- Klein M, Birch D.. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc Ophthalmol. 2009; 119: 217–224.
- Dacey DM, Petersen MR.. Dendritic field size and morphology of midget and parasol ganglion cells of the human retina. P Natl Acad Sci USA. 1992; 89: 9666–9670.
- Barnes N, Scott AF, Lieby P, et al. .. Vision function testing for a suprachoroidal retinal prosthesis: effects of image filtering. J Neural Eng. 2016; 13: 15.
- Saunders AL, Williams CE, Heriot W, et al. .. Development of a surgical procedure for implantation of a prototype suprachoroidal retinal prosthesis. Clin Exp Ophthalmol. 2014; 42: 665–674.
- Shivdasani MN, Sinclair NC, Dimitrov PN, et al. .. Factors affecting perceptual thresholds in a suprachoroidal retinal prosthesis. Invest Ophthalmol Vis Sci. 2014; 55: 6467–6481.
- Ayton LN, Rizzo JF III, Bailey IL, et al. .. Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the International HOVER Taskforce. Transl Vis Sci Technol. 2020; 9: 25.
- Ahuja AK, Behrend MR.. The Argus II retinal prosthesis: factors affecting patient selection for implantation. Prog Retin Eye Res. 2013; 36: 1–23.
- Petoe MA, McCarthy CD, Shivdasani MN, et al. .. Determining the contribution of retinotopic discrimination to localization performance with a suprachoroidal retinal prosthesis. Invest Ophth Vis Sci. 2017; 58: 3231–3239.
- Bach M, Wilke M, Wilhelm B, Zrenner E, Wilke R.. Basic quantitative assessment of visual performance in patients with very low vision. Invest Ophth Vis Sci. 2010; 51: 1255–1260.
- Humayun MS, Dorn JD, da Cruz L, et al. .. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012; 119: 779–788.
- Finger RP, McSweeney SC, Deverell L, et al. .. Developing an instrumental activities of daily living tool as part of the low vision assessment of daily activities protocol. Invest Ophth Vis Sci. 2014; 55: 8458–8466.
- Geruschat DR, Flax M, Tanna N, et al. .. FLORA: phase I development of a functional vision assessment for prosthetic vision users. Clin Exp Optom. 2015; 98: 342–347.
- Finger RP, Tellis B, Crewe J, Keeffe JE, Ayton LN, Guymer RH.. Developing the Impact of Vision Impairment-Very Low Vision (IVI-VLV) Questionnaire as part of the LoVADA protocol. Invest Ophth Vis Sci. 2014; 55: 6150–6158.
- Kroenke K, Spitzer RL, Williams JB.. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16: 606–613.
- Wittkowski KM.Friedman-type statistics and consistent multiple comparisons for unbalanced designs with missing data. J Am Stat Assoc. 1988; 83: 1163–1170.
- R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available at: .
- Wittkowski KM, Song T.. muStat: Prentice rank sum test and McNemar test. R package version 1.7.0. Vienna, Austria: R Foundation for Statistical Computing; 2012. Available at: .
- Conover WJ.Practical nonparametric statistics. New York: John Wiley & Sons; 1998.
- Holm S.A simple sequentially rejective multiple test procedure. Scand J Stat. 1979; 6: 65–70.
- Ghodasra DH, Chen A, Arevalo JF, et al. .. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016; 16: 52.
- Muqit MMK, Hubschman JP, Picaud S, et al. .. PRIMA subretinal wireless photovoltaic microchip implantation in non-human primate and feline models. PloS One. 2020; 15: e0230713.
- Schaffrath K, Schellhase H, Walter P, et al. .. One-year safety and performance assessment of the Argus II retinal prosthesis: a postapproval study. Jama Ophthalmol. 2019; 137: 896–902.
- Luo YH-L, Zhong JJ, da Cruz L.. The use of Argus II retinal prosthesis by blind subjects to achieve localisation and prehension of objects in 3-dimensional space. Graefes Arch Clin Exp Ophthalmol. 2014; 253: 1907–1914.
- Curcio CA, Allen KA.. Topography of ganglion cells in human retina. J Comp Neurol. 1990; 300: 5–25.
- Yue L, Weiland JD, Roska B, Humayun MS.. Retinal stimulation strategies to restore vision: fundamentals and systems. Prog Retin Eye Res. 2016; 53: 21–47.
- Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Marmor M, Marc RE.. Retinal remodeling in human retinitis pigmentosa. Exp Eye Res. 2016; 150: 149–165.
- Ahuja AK, Dorn JD, Caspi A, et al. .. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011; 95: 539–543.
- Dorn JD, Ahuja AK, Caspi A, et al. .. The Detection of motion by blind subjects with the epiretinal 60-electrode (Argus II) retinal prosthesis. JAMA Ophthalmol. 2013; 131: 183–189.
- Titchener SA, Kvansakul J, Shivdasani MN, et al. .. Oculomotor responses to dynamic stimuli in a 44-channel suprachoroidal retinal prosthesis. Transl Vis Sci Technol. 2020; 9: 31–31.
- Stingl K, Bartz-Schmidt KU, Besch D, et al. .. Subretinal visual implant Alpha IMS – clinical trial interim report. Vision Res. 2015; 111: 149–160.
- Stingl K, Schippert R, Bartz-Schmidt KU, et al. .. Interim results of a multicenter trial with the new electronic subretinal implant Alpha AMS in 15 patients blind from inherited retinal degenerations. Front Neurosci. 2017; 11: 445.
- Kartha A, Sadeghi R, Barry MP, et al. .. Prosthetic visual performance using a disparity-based distance-filtering system. Transl Vis Sci Technol. 2020; 9: 27–27.
- Endo T, Kanda H, Hirota M, Morimoto T, Nishida K, Fujikado T.. False reaching movements in localization test and effect of auditory feedback in simulated ultra-low vision subjects and patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2016; 254: 947–956.
- Stingl K, Bach M, Bartz-Schmidt KU, et al. .. Safety and efficacy of subretinal visual implants in humans: methodological aspects. Clin Exp Optom. 2013; 96: 4–13.
- Wilke R, Bach M, Wilhelm B, Durst W, Trauzettel-Klosinski S, Zrenner E.. Testing visual functions in patients with visual prostheses. Artificial Sight. New York: Springer; 2007;91–110.
- da Cruz L, Dorn JD, Humayun MS, et al. .. Five-year safety and performance results from the Argus II Retinal prosthesis system clinical trial. Ophthalmology. 2016; 123: 2248–2254.
- Finger RP, Ayton LN, Deverell L, et al. .. Developing a very low vision orientation and mobility test battery (O&M-VLV). Optom Vis Sci. 2016; 93: 1127–1136.
- Barry MP, Dagnelie G.. Hand-camera coordination varies over time in users of the Argus II retinal prosthesis system. Front Syst Neurosci. 2016; 10: 41.
- Sabbah N, Authie CN, Sanda N, Mohand-Said S, Sahel JA, Safran AB.. Importance of eye position on spatial localization in blind subjects wearing an Argus II retinal prosthesis. Invest Ophth Vis Sci. 2014; 55: 8259–8266.
- Turano KA, Geruschat DR, Baker FH, Stahl JW, Shapiro MD.. Direction of gaze while walking a simple route: persons with normal vision and persons with retinitis pigmentosa. Optom Vis Sci. 2001; 78: 667–675.
- McCarthy C, Walker JG, Lieby P, Scott A, Barnes N.. Mobility and low contrast trip hazard avoidance using augmented depth. J Neural Eng. 2014; 12: 016003.
- Garcia S, Petrini K, Rubin GS, Da Cruz L, Nardini M. Visual and non-visual navigation in blind patients with a retinal prosthesis. PloS One. 2015; 10: e0134369.
- Caspi A, Roy A, Wuyyuru V, et al. .. Eye movement control in the Argus II retinal-prosthesis enables reduced head movement and better localization precision. Invest Ophthalmol Vis Sci. 2018; 59: 792–802.
- Titchener SA, Shivdasani MN, Fallon JB, Petoe MA.. Gaze compensation as a technique for improving hand-eye coordination in prosthetic vision. Transl Vis Sci Technol. 2018; 7: 2.
- Geruschat DR, Richards TP, Arditi A, et al. .. An analysis of observer-rated functional vision in patients implanted with the Argus II retinal prosthesis system at three years. Clin Exp Optom. 2016; 99: 227–232.
- Delyfer MN, Gaucher D, Mohand-Saïd S, et al. .. Improved performance and safety from Argus II retinal prosthesis post-approval study in France. Acta Ophthalmol. 2020, doi:10.1111/aos.14728. Online ahead of print.
- Dagnelie G, Christopher P, Arditi A, et al. .. Performance of real-world functional vision tasks by blind subjects improves after implantation with the Argus II retinal prosthesis system. Clin Exp Ophthalmol. 2017; 45: 152–159.
- Misajon R, Hawthorne G, Richardson J, et al. .. Vision and quality of life: the development of a utility measure. Invest Ophthalmol Vis Sci. 2005; 46: 4007–4015.
- Duncan JL, Richards TP, Arditi A, et al. .. Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. Clin Exp Optom. 2017; 100: 144–150.
Source: PubMed